Comparison · NCT00433966-230cae64
Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Segment Binary Angiographic Restenosis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Segment Binary Angiographic Restenosis. Trial comparisons, record NCT00433966-230cae64. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00433966-230cae64
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.096 | 0.0798 | 0.115 | wilson | |
| Risk in group 2 | 0.232 | 0.189 | 0.28 | wilson | |
| Risk difference, group 1 minus group 2 | -0.136 | -0.187 | -0.0891 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.415 | 0.316 | 0.543 | log | |
| Odds ratio, group 1 over group 2 | 0.352 | 0.254 | 0.489 | log | |
| Number needed to treat, for one fewer participant with the outcome on Stent Arm - Paclitaxel-Eluting Stent than on Stent Arm - Bare Metal Stent | 7.37 | 5.35 | 11.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Stent Arm - Paclitaxel-Eluting Stent | To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:~1. reduced rates of target lesion revascularization for ischemia at 1 year~2. similar rates of death, reinfarction, stroke or stent thrombosis at 1 year~3. lower rates of analysis segment binary angiographic restenosis at 13 months~Bare metal stent: Uncoated bare metal stent~Paclitaxel-eluting stent: slow rate-release paclitaxel-eluting stent | 102 | 1,062 | OG000 |
| Group 2 | Stent Arm - Bare Metal Stent | To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:~1. reduced rates of target lesion revascularization for ischemia at 1 year~2. similar rates of death, reinfarction, stroke or stent thrombosis at 1 year~3. lower rates of analysis segment binary angiographic restenosis at 13 months~Bare metal stent: Uncoated bare metal stent~Paclitaxel-eluting stent: slow rate-release paclitaxel-eluting stent | 76 | 328 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Stent Arm - Segment Binary Angiographic Restenosis
- Description
- Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset).
- Time frame
- 13 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
- NCT number
- NCT00433966
- Phases
- PHASE3
- Conditions
- Myocardial Infarction
- Interventions
- Bivalirudin, Unfractionated heparin, Bare metal stent, Paclitaxel-eluting stent
- Lead sponsor
- Cardiovascular Research Foundation, New York
- Results first posted
- 2017-12-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00433966?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00433966-230cae64